Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled multicenter study of Lianmei Granules in type 2 diabetes mellitus with qi-yin deficiency syndrome
CTR20191646Phase 2Active
- Sponsor
- Guangdong New South Artemisinin Pharmaceutical
- Start
- Sep 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Lianmei Granules in type 2 diabetes mellitus (T2DM), sponsored by Guangdong New South Artemisinin Pharmaceutical. Started Sep 2020; status: active.
02
Drugs
Lianmei Granules
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20191646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191646.